Original Article | Published:

Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial

Hypertension Research volume 31, pages 15831588 (2008) | Download Citation

Abstract

The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were −5.55 mmHg (95% confidence interval [CI], −10.5 to −0.57 mmHg; p <0.05) and −2.84 mmHg (CI, −5.33 to −0.33 mmHg; p >0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was −1.17 ng/mL/h for the nattokinase group compared with the control group (p <0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.

References

  1. 1.

    , , , , , : Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 ( 9455): 217–223.

  2. 2.

    , , , et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

  3. 3.

    , , , et al, InterASIA Collaborative Group: The International Collaborative Study of Cardiovascular Disease in ASIA. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 2002; 40: 920–927.

  4. 4.

    , , , et al: Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006; 24: 1515–1521.

  5. 5.

    , , , et al; National High Blood Pressure Education Program Coordinating Committee: Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288: 1882–1888.

  6. 6.

    , , , et al: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713–724.

  7. 7.

    , , , et al: Comparison of the effect of blood pressure on the development of stroke, acute myocardial infarction, and end-stage renal disease. Hypertens Res 2000; 23: 143–149.

  8. 8.

    , , , : Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation 1993; 88: 2771–2779.

  9. 9.

    , , , et al: The seven countries study: 2,289 deaths in 15 years. Prev Med 1984; 13: 141.

  10. 10.

    : Traditional soy foods: processing and products. J Nutr 1995; 125 ( 3 Suppl): 570S–572S.

  11. 11.

    , , , : Characterization of Nattokinase-degraded products from human fibrinogen or cross-linked fibrin. Fibrinolysis 1995; 9: 157.

  12. 12.

    , , , , , : Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun 1993; 197: 1340–1347.

  13. 13.

    , , , et al: The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001; 276: 24690–24696.

  14. 14.

    , , , et al: Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. Am J Hypertens 1999; 12: 697–704.

  15. 15.

    , : Nutrition for Living. San Francisco, The Benjamin/Cummings Publ Comp Inc, 1991, p 111.

  16. 16.

    American Dietetic Association: Handbook of Clinical Dietetics, 2nd ed, New Haven, Yale University Press, 1992, pp 5–39.

  17. 17.

    , , , , , : Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition 2003; 19: 261–264.

  18. 18.

    , , , et al: Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci 2003; 73: 1289–1298.

  19. 19.

    , , , , , : Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull 1995; 18: 1387–1391.

  20. 20.

    , , , : Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc 2006; 35: 139–142.

  21. 21.

    , ( eds): Effect of natto diet on blood pressure, in Basic and Clinical Aspects of Japanese Traditional Food Natto II. Japan Technology Transfer Association (JTTAS), 1998, pp 1–3.

  22. 22.

    , : The in vivo role of renin-angiotensin system. Cell Science 1992; 8: 146–151.

  23. 23.

    , , , : Antihypertensive substances in fermented soybean, natto. Plant Foods Hum Nutr 1995; 47: 39–47.

  24. 24.

    , , , , : Angiotensin I—converting enzyme inhibitory peptides isolated from tofuyo fermented soybean food. Biosci Biotechnol Biochem 2003; 67: 1278–1283.

Download references

Author information

Affiliations

  1. Yonsei University Research Institute of Science for Aging, Yonsei University, Seoul, Korea

    • Ji Young Kim
    • , Kyong-chol Kim
    • , Yangsoo Jang
    •  & Jong Ho Lee
  2. National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University, Seoul, Korea

    • Ji Young Kim
    • , Si Nae Gum
    • , Jean Kyung Paik
    • , Hyo Hee Lim
    •  & Jong Ho Lee
  3. Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, Korea

    • Si Nae Gum
    • , Hyo Hee Lim
    •  & Jong Ho Lee
  4. Department of Food and Nutrition, Brain Korea 21 Project, Yonsei University, Seoul, Korea

    • Jean Kyung Paik
    •  & Jong Ho Lee
  5. Seoul Fellowship, Seoul, Korea

    • Jean Kyung Paik
  6. Department of Family Medicine, Mizmedi Hospital, Seoul, Korea

    • Kyong-chol Kim
  7. Japan Bio Science Laboratory Co., Ltd., Ibaraki, Osaka, Japan

    • Kazuya Ogasawara
    •  & Kenichi Inoue
  8. Cardiology Division, Yonsei University College of Medicine, Yonsei Cardiovascular Center, Seoul, Korea

    • Sungha Park
    •  & Yangsoo Jang
  9. Cardiovascular Genome Center, Yonsei Medical Institute, Yonsei University, Seoul, Korea

    • Yangsoo Jang

Authors

  1. Search for Ji Young Kim in:

  2. Search for Si Nae Gum in:

  3. Search for Jean Kyung Paik in:

  4. Search for Hyo Hee Lim in:

  5. Search for Kyong-chol Kim in:

  6. Search for Kazuya Ogasawara in:

  7. Search for Kenichi Inoue in:

  8. Search for Sungha Park in:

  9. Search for Yangsoo Jang in:

  10. Search for Jong Ho Lee in:

Corresponding author

Correspondence to Jong Ho Lee.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1291/hypres.31.1583

Further reading